Latest Conference Articles

March 3rd 2023, 10:02pm

PER® Miami Breast Cancer Conference

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

March 3rd 2023, 9:25pm

PER® Miami Breast Cancer Conference

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

March 3rd 2023, 8:26pm

PER® Miami Breast Cancer Conference

With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.

March 3rd 2023, 8:20pm

PER® Miami Breast Cancer Conference

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

March 3rd 2023, 6:55pm

PER® Miami Breast Cancer Conference

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

March 3rd 2023, 5:55pm

PER® Miami Breast Cancer Conference

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

March 3rd 2023, 2:16pm

PER® Miami Breast Cancer Conference

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

March 1st 2023, 10:52pm

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

February 28th 2023, 9:05pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

February 28th 2023, 8:09pm

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

February 28th 2023, 7:59pm

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

February 28th 2023, 6:00pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

February 27th 2023, 10:53pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

February 27th 2023, 8:40pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

February 27th 2023, 8:03pm

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

February 25th 2023, 11:00am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

February 24th 2023, 10:13pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

February 24th 2023, 10:09pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

February 24th 2023, 9:52pm

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

February 24th 2023, 8:45pm

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.